Medication Affordability and Patent Integrity Act

This proposal would require drug makers and holders of approved drugs to share certain filings and messages with the Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO). The goal is to make sure both agencies have the same information about a medicine’s approvals and patent claims, which can help with oversight and clarity for the public and the market .

It also includes a section about a “non-disclosure defense” related to drug patents, which suggests the bill addresses what happens if required information isn’t shared. The exact details of that defense aren’t provided in the document excerpt, but the topic is explicitly listed .

• Who is affected: Companies that apply for drug approval or hold approved drug applications
• What changes: They must provide specified submissions and communications to both FDA and USPTO; the bill also touches on a defense tied to non-disclosure in drug patent cases
• When: The document does not include timing details in the provided text